Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position'
Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position'
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) announced its financial results for the first quarter ended March 31, 2024. The pharmaceutical company specializing in precision-based cannabinoids revealed a revenue increase of 67% to $9.8 million versus revenue for the same quarter in 2023 of $5.8 million.
MediPharm Labs Corp. (tsx:LABS) (otcqb:MEDIF) (FSE: MLZ)公佈了截至2024年3月31日第一季度的財務業績。這家以精準基礎大麻爲主的藥品公司公佈，其營業收入增長了67%，達到了980萬美元，而2023年同一季度的營業收入爲580萬美元。
"This quarter shows another quarter of growing revenue, stronger gross profit, decreasing costs and improving Adjusted EBITDA," stated David Pidduck, CEO. "MediPharm's balance sheet is in an excellent position to consider future investments in growth. With Adjusted EBITDA getting close to breakeven, the leadership team can now devote even more energy to growing our business. Regulatory changes in Germany and Australia and potential upcoming changes in the US are all very favorable for the company."
“本季度的業績再次顯示出營收增長、毛利潤增強、成本下降以及調整後的息稅前利潤（EBITDA）改善，”首席執行官David Pidduck表示。 “MediPharm的資產負債表處於一個非常良好的狀態，可以考慮未來的創業板投資。隨着調整後的EBITDA接近盈虧平衡，領導團隊現在可以更多地投入精力來發展業務。德國和澳大利亞的監管變化以及美國可能即將出現的變化，對公司都非常有利。”
More about investments and financial data from the industry you can hear at the 19th Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's future. Secure your tickets now before prices increase by following this link.
有關行業投資和財務數據的更多信息，請參加10月8日至9日在芝加哥舉行的第19屆Benzinga大麻資本大會。與高管、投資者、決策者和倡導者互動，探索該行業的未來。點擊鏈接預定門票，現在可以在價格上漲之前獲得門票。此鏈接.
Q1 Financial Summary
2024年第一季度財務摘要
- Gross profit was $2.7 million or 27% which improved significantly versus the first quarter 2023 gross profit of 6.6% and versus the fourth quarter of last year of 24.3%.
- Adjusted EBITDA improved 70% to a loss of $900,000 from a loss of $3.1 million in the same period of 2023, and improved sequentially from a loss of $1.6 million in the prior quarter.
- Net loss amounted to $3.6 million, compared to a loss of $3.09 million in the same period of last year.
- As of March, 31, 2023 the company reported a balance sheet with $17 million in cash and less than $3 million in debt.
- 毛利潤爲270萬美元，佔比27%，這與2023年第一季度的毛利潤6.6%相比有了顯著的改善，也比去年第四季度的24.3%有所改善。
- 調整後的EBITDA從2023年同期的310萬美元損失，上升70%至90萬美元損失，並從上一季度的160萬美元損失上升。
- 淨虧損爲360萬美元，而去年同期虧損309萬美元。
- 截至2023年3月31日，公司資產負債表顯示現金1700萬美元，負債不足300萬美元。
Greg Hunter, CFO, MediPharm Labs added, "Q1 2024 was another step in the right direction towards profitability and becoming cash flow positive. Our revenue and Adjusted EBITDA were both the highest in over 3 years. Revenue was $9.8 million or 67% higher than the prior year and Adjusted EBITDA loss was $0.9 million which is $2.1 million better than the prior year. Our cash burn was approximately $1 million resulting in an ending cash balance of $17 million with less than $3 million of debt. MediPharm is in a strong financial position to capitalize on our strong suite of licenses, global customer contracts and assets as we strive for profitability in 2024."
“2024年第一季度是我們向盈利和現金流轉正邁出的又一步。我們的收入和調整後的EBITDA都是三年來最高的。營收爲980萬美元，比去年同期增長了67%，而調整後的EBITDA損失爲90萬美元，比去年的210萬美元有所改善。我們的現金燃燒約爲100萬美元，最終現金餘額爲1700萬美元，負債不足300萬美元。作爲我們努力在2024年實現盈利能力的組合持牌、全球客戶合約和資產的有力支持下，MediPharm處於強有力的財務地位。”公司CFO Greg Hunter補充說。
The company said it anticipates further improvement in profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1 million to $2 million, which plans include the ongoing optimization of production and logistics facilities.
公司表示，預計2024年的盈利能力將進一步提高，並計劃通過持續優化生產和物流設施等舉措將調整後的EBITDA進一步提高100萬至200萬美元。
Price Action
價格走勢
MediPharm Labs shares traded flat at $26.44 per share during Wednesday's pre-market session.
週三盤前，MediPharm Labs的股票以26.44美元的價格持平。
Photo: Courtesy of Branding Pot via Shutterstock
圖片：由Brand Pot通過Shutterstock提供。